Rinvoq ER 15 MG tablet UU 30S
Ended Awarded Last action
- Contract number
- SPE2DR26FZ5AP
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $20,829
Award facts
- Contract value 100% obligated
- $20,829.46 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $20,829.46 delivery order to AmerisourceBergen Drug Corp (parent company Cencora, Inc.) on February 2, 2026, for RINVOQ ER 15 mg tablets in a 30-count unit dose package. This firm fixed-price contract is non-set-aside and was competitively awarded, with an ultimate completion date of February 3, 2026. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a task order executed under AmerisourceBergen's substantially larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026, which serves as the company's primary vehicle for supplying pharmaceutical products and medical supplies to support military healthcare programs globally.
RINVOQ (upadacitinib) is a JAK inhibitor used to treat rheumatoid arthritis and other inflammatory conditions, reflecting the type of specialized pharmaceutical products that the Defense Logistics Agency procures to support military treatment facilities and veterans' healthcare programs. AmerisourceBergen's position as a major pharmaceutical distributor and critical vendor in the federal medical supply chain, combined with its demonstrated capability to manage substantial contract values and diverse product portfolios across multiple therapeutic domains, underscores its role in ensuring consistent access to essential medications for military personnel and beneficiaries.
Quick answers
Who was awarded contract SPE2DR26FZ5AP?
SPE2DR26FZ5AP was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on February 2, 2026.
How much is contract SPE2DR26FZ5AP worth?
The government has obligated $20,829 on SPE2DR26FZ5AP.
Is contract SPE2DR26FZ5AP an order under another contract?
Yes. SPE2DR26FZ5AP is a delivery order under SPE2DR25D1050, an indefinite delivery contract.
Was contract SPE2DR26FZ5AP competed?
The extent of competition for SPE2DR26FZ5AP was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award